2015 and Older Webinars
Collapse Association for Molecular Pathology v. Myriad Genetics, Inc.

Learn about the trial and the seminal ruling of the Association for Molecular Pathology v. Myriad Genetics U.S. Supreme Court case. Hear from one of ACLU's key attorney who handled the case and learn about the implications of the rulings in this two-part webinar.

 

Part 1: Review of the Gene Patent Supreme Court Case

Speakers: Sandra Park, JD

Host: Ted E. Schutzbank, PhD

Duration: 1 hr

Level of Instruction: Basic

 

Part 2: Association for Molecular Pathology v Myriad Genetics, Inc.

Speakers: Sandra Park, JD and Roger D. Klein, MD, JD

Host: Ted E. Schutzbank, PhD

Duration: 1 hr

Level of Instruction: Basic to Intermediate

 

All sales are final. No refunds will be issued.

Note: This is a free webinar for all. For access to other webinars at no cost, Join the AMP Family!

Formats Available: Streaming
Original Course Date: June 28, 2013
MORE INFOMORE INFO Association for Molecular Pathology v. Myriad Genetics, Inc.
Collapse Next-Generation Sequencing (NGS) Technologies for HIV Drug Resistance Testing

Description:

HIV-1 exists within individuals as a complex mixture of variants often referred to as a quasispecies. During the past 10 years, there have been many studies of the distribution and clinical significance of "low-abundance" or "minority" drug-resistance variants present in plasma in proportions below 20% to 30% -- the limit of detection of standard genotypic resistance testing using dideoxy-terminator "Sanger" sequencing. HIV-1 "deep" sequencing using NGS technologies have been widely used in research settings to study the clinical significance of low-abundance drug resistance mutations. In addition, NGS is commercially available for several niche clinical applications such as determining HIV-1 tropism before using a CCR5 inhibitor.

In this webinar, Dr. Shafer will review the scenarios in which low-abundance HIV-1 drug-resistance mutations are most clinically relevant, the most influential studies of NGS for HIV-1 drug resistance testing, and the practical aspects of NGS that have so far slowed its widespread adoption for most routine HIV-1 genotypic resistance testing.

This content is now FREE for all but, continuing education credit is not available.

 

Speaker: Robert W. Shafer MD

Duration: 1.0 hrs.

Level of Instruction: Basic

Reviewed: March, 2018 

  • The material presented is still relevant.

 

All sales are final. No refunds will be issued.

Members of AMP can access this webinar at no cost. Join the AMP Family!

Formats Available: Streaming
Original Course Date: June 18, 2015
MORE INFOMORE INFO Next-Generation Sequencing (NGS) Technologies for HIV Drug Resistance Testing